China Approves Bayer’s Sevabertinib as First-Line Treatment for HER2-Mutated Lung Cancer
The approval expands sevabertinib’s approved use in China to first-line treatment for lung cancer with a HER2 mutation.
The approval expands sevabertinib’s approved use in China to first-line treatment for lung cancer with a HER2 mutation.